Cdc35 Inhibitors
Cdc35 inhibitors are compounds primarily centered around modulating the cAMP-PKA signaling pathway, in which CYR1 (adenylate cyclase) plays a crucial role. Compounds such as SQ22536 and MDL-12,330A directly target adenylate cyclase activity, suppressing the production of cAMP. Given that CYR1 is pivotal for cAMP synthesis in yeast, these compounds can notably inhibit its functionality. On the other hand, several inhibitors target downstream components like PKA. H89, KT5720, and PKI 14-22 amide, all PKA inhibitors, can modulate CYR1 activity indirectly, possibly through feedback mechanisms.
Moreover, the cAMP-PKA pathway doesn't operate in isolation. Adenosine receptors, which play a role in modulating adenylate cyclase activity, become targets for compounds like ZM241385, SCH442416, and DPCPX. By antagonizing these receptors, the cellular response to adenylate cyclase activation can change, influencing CYR1's role in the process. Similarly, pertussis toxin targets G-protein coupled receptor signaling, and given the interplay between GPCRs and adenylate cyclase, it too can have an impact on CYR1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SQ 22536 | 17318-31-9 | sc-201572 sc-201572A | 5 mg 25 mg | $93.00 $356.00 | 13 | |
Adenylate cyclase inhibitor that can suppress cAMP production. Suppressing cAMP synthesis can reduce CYR1 activity. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $92.00 $182.00 | 71 | |
Inhibits protein kinase A (PKA), which is downstream of CYR1. By inhibiting PKA, feedback mechanisms can modulate CYR1 activity. | ||||||
Rp-cAMPS | 151837-09-1 | sc-24010 | 1 mg | $199.00 | 37 | |
cAMP analog that can act as a competitive inhibitor for cAMP-dependent processes. Can modulate pathways where CYR1-produced cAMP would act. | ||||||
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $97.00 $144.00 $648.00 | 47 | |
PKA inhibitor that can indirectly affect upstream activators or components, possibly including CYR1. | ||||||
PKI (14-22) amide (myristoylated) | 201422-03-9 | sc-471154 | 0.5 mg | $132.00 | 2 | |
Inhibits PKA, and through feedback or crosstalk, can influence CYR1-related processes. | ||||||
ZM 241385 | 139180-30-6 | sc-361421 sc-361421A | 5 mg 25 mg | $90.00 $349.00 | 1 | |
Adenosine A2A receptor antagonist. By modulating adenosine signaling, it can influence adenylate cyclase activity, including CYR1. | ||||||
SCH 442416 | 316173-57-6 | sc-204271 sc-204271A | 1 mg 10 mg | $95.00 $245.00 | 3 | |
Adenosine A2A receptor antagonist. Similar to ZM241385, it can affect adenylate cyclase activities by influencing adenosine signaling. | ||||||
PD 116,948 | 102146-07-6 | sc-200115 sc-200115A | 25 mg 100 mg | $122.00 $224.00 | 6 | |
Adenosine A1 receptor antagonist. By targeting adenosine receptors, adenylate cyclase pathways can be influenced, possibly affecting CYR1. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
While primarily known as a c-Raf inhibitor, its broader effects on signaling pathways can potentially intersect with the CYR1-involved cAMP-PKA pathway. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $442.00 | 3 | |
Inhibits G-protein coupled receptor signaling. Given that GPCRs can activate adenylate cyclase, pertussis toxin can potentially reduce CYR1 activity. | ||||||